Trial · NCT00723021
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) | Baseline, 12 hours (hrs) post-dose | The FEV1 is the maximal volume of air that can be forcefully exhaled in one second |
| Primary | Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) | Baseline, 24 hours (hrs) post-dose | The FEV1 is the maximal volume of air that can be forcefully exhaled in one second |
| Secondary | Change From Baseline in Forced Vital Capacity (FVC) | Baseline, 12 hours (hrs) post-dose | The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible |
| Secondary | Change From Baseline in Forced Vital Capacity (FVC) | Baseline,24 hours (hrs) post-dose | The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible |
| Secondary | Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75) | Baseline, 12 hours (hrs) post-dose | The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity |
| Secondary | Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75) | Baseline, 24 hours (hrs) post-dose | The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity |
| Other | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) | Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period. | Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) |
| Other | Maximum Observed Plasma Concentration (Cmax) | Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period. | |
| Other | Time to Reach Maximum Observed Plasma Concentration (Tmax) | Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period. | |
| Other | Plasma Decay Half-Life (t1/2) | Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period. | Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. |
| Other | Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] | 14 and 24 hours following dosing in each period. | AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00723021/registered